Primary Immunodeficiency Diseases: all 204 studies

Page 2 of 3. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.

• Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited DisordersTerminatedNCT00358657Phase 2Results posted
• Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00322556Phase 3Results posted
• Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.CompletedNCT00278954Phase 3Results posted
• An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CompletedNCT07076446Phase 4
• CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary ImmunodeficiencyActive, not recruitingNCT07015801Not applicable
• Virtual Reality on Pain and Fear Levels of Children With Primary ImmunodeficiencyCompletedNCT07004803Not applicable
• Leniolisib for Immune Dysregulation in PIDsCompletedNCT06549114Phase 2
• Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, FranceCompletedNCT06355323Not applicable
• Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.Active, not recruitingNCT06276036Not applicable
• At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa SkillCompletedNCT06150534
• Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary ImmunodeficiencyStatus unknownNCT06092528Not applicable
• A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency DiseasesActive, not recruitingNCT06076642Phase 3
• Evaluation of Adult Patients With Immunodeficiency Within the Scope of the ICFCompletedNCT06014463
• Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary ImmunodeficienciesStatus unknownNCT05986734
• Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in PakistanCompletedNCT05758506
• Pediatric Intensive Care Unit and Primary Immune DeficiencyCompletedNCT05629247Not applicable
• Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in TunisiaCompletedNCT05621876
• A Prospective Monocentric Study to Assess the Concordance of Lung MRI Compared to Chest CT Scan to Assess the Extent and Severity of Bronchial and Parenchymal Pulmonary Lesions in Adult Patients With Primary Immune Deficiency (PID) .Status unknownNCT05476653Not applicable
• COVID-19 Vaccine Responses in PIDD SubjectsActive, not recruitingNCT05321407
• Early Detection of Primary Antibody Deficiencies in Primary Care Facilities by an Algorithm Driven Selection of Serologic Testing in Individuals at Risk.CompletedNCT05310604
• An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)Status unknownNCT05070455Phase 4
• Primary Immunodeficiencies in Costa Rican AdultsCompletedNCT04963660
• Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)Active, not recruitingNCT04944979Phase 3
• Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary ImmunodeficienciesCompletedNCT04919018
• Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and InflammationCompletedNCT04902807
• Immunoglobulin G Therapy Dose OptimizationCompletedNCT04818177
• COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune DeficiencyStatus unknownNCT04724642
• Defining the Genetic Etiology of Suppurative Lung Disease in Children and AdultsCompletedNCT04702243
• Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency DiseasesActive, not recruitingNCT04640142Phase 3
• Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID)CompletedNCT04636502
• Primitive Immunodeficiency and PregnancyCompletedNCT04581460
• Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.Status unknownNCT04572620
• Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral ImmunodeficiencyActive, not recruitingNCT04565015Phase 3
• Systematic Screening for Primary Immunodeficiencies in Patients Hospitalized for Severe Infections in Intensive Care.Status unknownNCT04356053
• Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)Status unknownNCT04354818
• Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.Active, not recruitingNCT04354129
• Minipooled-IVIG in Primary Immunodeficiency DiseaseCompletedNCT03896932Not applicable
• Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell TransplantationStatus unknownNCT03836690Phase 1
• What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?CompletedNCT03815357
• Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary ImmunodeficiencyWithdrawnNCT03814798Phase 3
• Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)CompletedNCT03716700
• Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) TreatmentStatus unknownNCT03677557Phase 4
• Tolerance and Patients' Satisfaction With IGHyStatus unknownNCT03668288
• Severe Immune Cytopenia Registry Www.Sic-reg.OrgCompletedNCT03576742
• Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral ImmunodeficiencyWithdrawnNCT03492710Phase 3
• Severe PID With Lymphoproliferation and NeutropeniaCompletedNCT03427593Not applicable
• Identification of New Inborn Errors of ImmunityCompletedNCT03414528
• Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ SyndromeCompletedNCT03383380Phase 1/2
• The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG PreparationsCompletedNCT03339778
• Improving the Diagnosis of Common Variable Immune DeficiencyCompletedNCT03335605
• Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantActive, not recruitingNCT03301168Phase 1/2
• Pediatric Primary Immunodeficiency Disease (PID) in ChinaStatus unknownNCT03252548
• The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency DiseaseCompletedNCT03211689Not applicable
• Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16CompletedNCT03164967Phase 4
• Immunological Characteristics of Patients With PID and IBDStatus unknownNCT03148028
• Investigation of Dental Health in Children With Neutrophil Defects: A Clinical StudyCompletedNCT03069079Not applicable
• Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO)CompletedNCT03054181
• A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin ProductsStatus unknownNCT03037359
• Evaluation of the Efficacy of the Sequencing Method by Gene-panelCompletedNCT02954640Not applicable
• Study of Gut Microbiota in Primary Immune Deficiency, Possibly Associated With Inflammatory Bowel DiseaseCompletedNCT02909244
• Intensive Care Unit and Secondary and Primary Immune DeficiencyCompletedNCT02888535
• IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQviaCompletedNCT02881437Phase 4
• Determinants of Health Status and Quality of Life in Patients With Primary Immunodeficiencies Inhereted Diagnosed During ChildhoodStatus unknownNCT02868333
• Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or MalignanciesNo longer availableNCT02822495
• Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly SchedulesCompletedNCT02711228Phase 4
• Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)CompletedNCT02593188
• Construction of a Health-related Quality of Life (HR-QOL) Questionnaire for Patients With Primary Antibody Deficiency DiseaseCompletedNCT02542228
• A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid PushCompletedNCT02503293Phase 4
• Diagnostic Immunization With Rabies Vaccine in Patients With PIDStatus unknownNCT02490956Phase 4
• A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®CompletedNCT02247141Phase 3
• Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or PumpsCompletedNCT02180763Phase 4
• Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home SettingCompletedNCT02176239
• ASIS for GAMMAGARD in Primary ImmunodeficiencyStatus unknownNCT02123615Phase 1/2
• Pharmacokinetics and Safety of IVIG Nanogam 100 mg/mlCompletedNCT01985373Phase 3
• Investigation of Immune Disorders and DeficienciesStatus unknownNCT01981785
• CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell TransplantationActive, not recruitingNCT01966367Phase 1/2
• Participation in a Research Registry for Immune DisordersCompletedNCT01953016
• Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)TerminatedNCT01883921
• Octagam 5% Versus Comparator Post Marketing TrialCompletedNCT01859754
• Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)Status unknownNCT01617122Not applicable
• Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)CompletedNCT01461018Phase 3
• Immune Globulin Subcutaenous (Human), 20%CompletedNCT01412385Phase 2/3
• Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary ImmunodeficiencyCompletedNCT01406470Phase 3
• Evaluation of Efficacy and Tolerability of Hizentra®Status unknownNCT01354587Not applicable
• Gene Therapy for Wiskott-Aldrich Syndrome (WAS)CompletedNCT01347242Phase 1/2
• Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional StudyCompletedNCT01287689
• Retrospective Chart Review of Subcutaneous IgG Use in InfantsCompletedNCT01166074
• Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in SwitzerlandStatus unknownNCT01150240
• Study of Vitamin D3 Substitution to Patients With Primary ImmunodeficiencyCompletedNCT01131858Phase 1/2
• Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV SubcutaneouslyCompletedNCT00782106Phase 1/2
• Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood CellsCompletedNCT00692926Phase 1
• Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary ImmunodeficiencyCompletedNCT00680446Phase 3
• Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous ImmunoglobulinCompletedNCT00661401Not applicable
• Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)CompletedNCT00405184Phase 3
• Subcutaneous Ig NextGen 16% in PID PatientsCompletedNCT00391131Phase 3
• Studies of Disorders in Antibody Production and Related Primary Immunodeficiency StatesTerminatedNCT00266513
• Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168025Phase 3
• Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168012Phase 3
• Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)CompletedNCT00161993Phase 2
• Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency DisordersCompletedNCT00157079Phase 3

← Primary Immunodeficiency Diseases overview